Sangamo and Pfizer entered an exclusive global collaboration for SB-525 hemophilia A gene therapy and additional cDNA AAV programs. Sangamo received $70M upfront plus eligibility for up to $475M in milestones ($300M for SB-525 development/commercialization) plus tiered double-digit royalties. Pfizer assumed responsibility for global pivotal development, manufacturing and commercialization following Phase 1/2.
Key facts
AnnouncedMay 10, 2017
Deal value$545M
Deal typeLicensing/Option
Therapeutic areaHemophilia A
IndicationsHemophilia A
Key assetsSB-525 (giroctocogene fitelparvovec)
MechanismrAAV vector-delivered Factor VIII gene therapy